Shots:
The P-III (HICKORY) trial data assessed efzimfotase alfa (ALXN1850; Q2W, SC) vs PBO in 124 pts (≥12yrs.) with HPP who have not been previously treated with Strensiq;data were presented at ASBMR 2026
At Wk. 25, ALXN1850 did not significantly improve 6MWT (1EP), achieving a LS mean difference of 17.05m, while FACIT-Fatigue showed nominally significant…
